MedTrace Logo

Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke

NCT00860366 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 421

Last updated 2015-03-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether the combined treatment with Uric Acid and rtPA is superior to rtPA alone in terms of clinical efficacy in acute ischemic stroke patients treated within the first 4.5 hours of symptoms onset.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Uric Acid

1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.

OTHER

Vehicle

Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.

Sponsors & Collaborators

  • Carlos III Health Institute

    collaborator OTHER_GOV

  • Angel Chamorro, MD

    lead OTHER

Principal Investigators

  • Angel Chamorro, MD, PhD. · Comprehensive Stroke Center, Hospital Clínic Barcelona, Spain.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-08-31
Completion
2013-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860366 on ClinicalTrials.gov